Holen Sie sich die Stockscreener-App
0.4801
3.75%
-0.0187
Handel nachbörslich:
.49
0.0099
+2.06%
Schlusskurs vom Vortag:
$0.4988
Offen:
$0.4746
24-Stunden-Volumen:
5.05M
Relative Volume:
1.71
Marktkapitalisierung:
$81.10M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-111.13M
KGV:
-0.3637
EPS:
-1.32
Netto-Cashflow:
$-91.53M
1W Leistung:
-15.79%
1M Leistung:
+5.52%
6M Leistung:
-72.88%
1J Leistung:
-89.76%
1-Tages-Spanne:
$0.4427
$0.5244
1-Wochen-Bereich:
$0.4427
$0.5799
52-Wochen-Spanne:
$0.4054
$4.96
Tenaya Therapeutics Inc Stock (TNYA) Company Profile
Firmenname
Tenaya Therapeutics Inc
Sektor
Branche
Telefon
415-865-2066
Adresse
171 OYSTER POINT BLVD., SUITE 500, SOUTH SAN FRANCISCO
Vergleichen Sie TNYA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TNYA
Tenaya Therapeutics Inc
|
0.4801 | 81.10M | 0 | -111.13M | -91.53M | -1.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.56 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.78 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
550.00 | 32.85B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.95 | 28.75B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
220.54 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Tenaya Therapeutics Inc Stock (TNYA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-06-10 | Eingeleitet | William Blair | Outperform |
| 2023-11-30 | Eingeleitet | Leerink Partners | Outperform |
| 2022-06-15 | Eingeleitet | H.C. Wainwright | Buy |
Tenaya Therapeutics Inc Aktie (TNYA) Neueste Nachrichten
Layoff Tracker: Spark Lays Off 298 Employees - BioSpace
Tenaya to lay off about one-third of staff, reveals heart gene therapy data - Endpoints News
Top 3 Insider Stock Buys in March-Are They Still Good in April? - MSN
Tenaya Therapeutics Announces Late Breaker Presentation of New Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 at American College of Cardiology Annual Meeting - GlobeNewswire
Revolutionary Gene Therapy Transforms Severe Heart Disease Patients in Landmark Trial - Stock Titan
Undervalued Cardiology Stocks to Watch: TNYA, MIST, BBIO, ALNY - GuruFocus
Tenaya Therapeutics IncOn Mar 27, Co Approves Restructuring PlanSEC Filing - MarketScreener
Is Tenaya Therapeutics, Inc. (TNYA) the Cheapest Stock Insiders Are Buying In March? - MSN
FY2025 Earnings Estimate for TNYA Issued By Chardan Capital - Defense World
Tenaya Therapeutics, Inc. (TNYA): Among Stocks Receiving the Most Insider Love in March - Yahoo
Top 3 Insider Stock Buys in March—Are They Still Good in April? - Benzinga
Tenaya Therapeutics publishes preclinical data on TN-201 in cardiac function - Yahoo Finance
Top 3 Insider Stock Buys In March—Are They Still Good In April? - Barchart.com
Breakeven On The Horizon For Tenaya Therapeutics, Inc. (NASDAQ:TNYA) - simplywall.st
Tenaya reports promising gene therapy for heart condition By Investing.com - Investing.com South Africa
Tenaya Therapeutics Says Gene Therapy Candidate Improves Heart Function in Preclinical Trial - MarketScreener
Tenaya reports promising gene therapy for heart condition - Investing.com India
Tenaya Therapeutics, Inc.'s (NASDAQ:TNYA) stock price dropped 13% last week; individual investors would not be happy - Yahoo Finance
Tenaya Therapeutics Publishes Preclinical Data Demonstrating TN-201 Enhances Cardiac Function and Survival in MYBPC3 Cardiomyopathy Models - GlobeNewswire
Revolutionary Heart Disease Treatment: Gene Therapy Reverses Cardiac Damage in Landmark Study - Stock Titan
Tenaya Therapeutics announces $300M mixed shelf offering; shares down - MSN
Tenaya Therapeutics files for mixed shelf offering of up to $300 mln -March 21, 2025 at 04:16 pm EDT - MarketScreener
Tenaya Therapeutics to Present New Data on MYBPC3-Associated Hypertrophic Cardiomyopathy at ACC 2025 Annual Scientific Session - Nasdaq
Tenaya Therapeutics Announces Late Breaker and New Data - GlobeNewswire
Major Breakthrough: Tenaya's Gene Therapy Trial Reveals Critical One-Year Heart Disease Data - StockTitan
Mineralys, Tenaya, SpringWorks, COSCIENS, Metagenomi: 5 Biotech Stocks That Led Retail Follower Growth Last Week - MSN
Canaccord Genuity Group Lowers Tenaya Therapeutics (NASDAQ:TNYA) Price Target to $6.00 - Defense World
Analysts Issue Forecasts for TNYA Q1 Earnings - Defense World
Biotech Alert: Searches spiking for these stocks today - Yahoo Finance
Morgan Stanley Has Lowered Expectations for Tenaya Therapeutics (NASDAQ:TNYA) Stock Price - Defense World
Chardan Capital Lowers Tenaya Therapeutics (NASDAQ:TNYA) Price Target to $9.00 - Defense World
What is HC Wainwright’s Estimate for TNYA Q1 Earnings? - Defense World
Canaccord cuts Tenaya Therapeutics price target to $6 By Investing.com - Investing.com South Africa
Canaccord cuts Tenaya Therapeutics price target to $6 - Investing.com
Q1 Earnings Forecast for TNYA Issued By Lifesci Capital - Defense World
Tenaya Therapeutics (NASDAQ:TNYA) Price Target Lowered to $5.00 at HC Wainwright - Defense World
Chardan Adjusts Price Target on Tenaya Therapeutics to $9 From $18, Keeps Buy Rating - Marketscreener.com
H.C. Wainwright cuts Tenaya Therapeutics price target to $5 By Investing.com - Investing.com Canada
Tenaya Therapeutics Advances Gene Therapy Pipeline - TipRanks
H.C. Wainwright cuts Tenaya Therapeutics price target to $5 - Investing.com
Insiders Are Loading Up on These 4 Biotech Stocks Now - 24/7 Wall St.
Tenaya Therapeutics SVP sells shares worth $1,334 By Investing.com - Investing.com Australia
Tenaya Therapeutics CEO Ali Faraz sells shares worth $5,244 By Investing.com - Investing.com Australia
Tenaya Therapeutics chief medical officer sells shares worth $3,982 By Investing.com - Investing.com South Africa
Finanzdaten der Tenaya Therapeutics Inc-Aktie (TNYA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):